Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

PURPOSE: This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase inhibitor RO4987655 (CH4987655) assessed its maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetic/pharmacodynamic profile, and antitumor activity in patients with advan...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Leijen, S, Middleton, MR, Tresca, P, Kraeber-Bodéré, F, Dieras, V, Scheulen, M, Gupta, A, Lopez-Valverde, V, Xu, Z, Rueger, R, Tessier, J, Shochat, E, Blotner, S, Naegelen, V, Schellens, J, Eberhardt, W
Natura:	Journal article
Lingua:	English
Pubblicazione:	2012

Documenti analoghi

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
di: Kraeber-Bodéré, F, et al.
Pubblicazione: (2012)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
di: Leijen, S, et al.
Pubblicazione: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
di: Leijen, S, et al.
Pubblicazione: (2011)

Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
di: Julia Koch-Heier, et al.
Pubblicazione: (2022-06-01)

Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S
di: Michel Theron, et al.
Pubblicazione: (2017-07-01)

Challenges in nuclear medicine: innovative theranostic tools for personalized medicine
di: Françoise eKraeber-Bodéré, et al.
Pubblicazione: (2014-07-01)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers
di: Joseph F. Grippo, et al.
Pubblicazione: (2021-07-01)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
di: Clément Bailly, et al.
Pubblicazione: (2019-04-01)

Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
di: Yan Zhang, et al.
Pubblicazione: (2025-02-01)

The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
di: Makoto Wada, et al.
Pubblicazione: (2014-01-01)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.
di: Appels, N, et al.
Pubblicazione: (2008)

Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
di: Jia‐yu Zhang, et al.
Pubblicazione: (2024-04-01)

Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2
di: Martin Bauer, et al.
Pubblicazione: (2024-02-01)

Fire Risk Model for Fires in Ro-Ro Ship Ro-Ro Spaces
di: Sixten Dahlbom, et al.
Pubblicazione: (2024-09-01)

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
di: Karthik Ramasamy, et al.
Pubblicazione: (2021-09-01)

NOP Receptor Agonist Ro 64-6198 Decreases Escalation of Cocaine Self-Administration in Rats Genetically Selected for Alcohol Preference
di: Hongwu Li, et al.
Pubblicazione: (2019-03-01)

Mek1 and Mek2 Functional Redundancy in Erythropoiesis
di: Laurent Beuret, et al.
Pubblicazione: (2021-07-01)

Ro-ro ships and shipping /
di: Grey, Michael
Pubblicazione: (1985)

Vehicles on ro/ro ships
di: 8096 British Standards Institution, et al.

Mek mulung
di: Malaysia. Kementerian Perpaduan, Kebudayaan, Kesenian dan Warisan. Jabatan Muzium dan Antikuiti, et al.
Pubblicazione: ([dat)

Mek mulung
di: Malaysia. Kementerian Kebudayaan, Belia dan Sukan. Bahagian Kebudayaan
Pubblicazione: (1981)

MEK Inhibition
di: Emilien Loeuillard, PhD, et al.
Pubblicazione: (2021-01-01)

Ro/ro ships (1978-1978)
di: British Ship Research Association
Pubblicazione: ([19-)

Some elements of the ro-ro terminals
di: R. Maksimavičius
Pubblicazione: (2004-04-01)

Safety, Pharmacokinetics/Pharmacodynamics, and Absolute Bioavailability of Dexmedetomidine Hydrochloride Nasal Spray in Healthy Subjects: A Randomized, Parallel, Escalating Dose Study
di: Yun Kuang, et al.
Pubblicazione: (2022-05-01)

Cell Tracking in Cancer Immunotherapy
di: Justine Perrin, et al.
Pubblicazione: (2020-02-01)

Real de-escalation or escalation in disguise?
di: Maggie Banys-Paluchowski, et al.
Pubblicazione: (2023-06-01)

AN ANALYSIS OF THE ITALIAN RO-RO AND RO-PAX NETWORK IN THE YEARS 2008-2015
di: Marino LUPI, et al.
Pubblicazione: (2017-12-01)

Consequences of escalation and de-escalation of double antiplatelet therapy in patients with acute coronary syndrome in real clinical practice
di: R. L. Shamraev, et al.
Pubblicazione: (2019-04-01)

Some features of roAp stars spectrum
di: A. V. Shavrina, et al.
Pubblicazione: (2017-03-01)

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
di: Xuan Wang, et al.
Pubblicazione: (2023-01-01)

Unveiling the Ro60-Ro52 complex
di: Laura R. Rodríguez, et al.
Pubblicazione: (2024-06-01)

»Ci-ce-ro! Ci-ce-ro!«
di: Marie Theres Fögen
Pubblicazione: (2007-01-01)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
di: Marc A. Simon, et al.
Pubblicazione: (2022-01-01)

[18F]-Fludarabine for Hematological Malignancies
di: Louisa Barré, et al.
Pubblicazione: (2019-04-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
di: Pacey, S, et al.
Pubblicazione: (2016)

The Pharmacodynamics of Antipsychotic Drugs in Women and Men
di: Mary V. Seeman
Pubblicazione: (2021-04-01)

Assessment of lymph nodes and prostate status using early dynamic curves with 18F-choline PET/CT in prostate cancer
di: Cédric eMathieu, et al.
Pubblicazione: (2015-09-01)

Focus on the controversial aspects of 64Cu-ATSM in tumoral hypoxia mapping by PET imaging
di: Mathilde eColombié, et al.
Pubblicazione: (2015-08-01)

Interest of Pet Imaging in Multiple Myeloma
di: Bastien Jamet, et al.
Pubblicazione: (2019-04-01)